<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134471">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01882179</url>
  </required_header>
  <id_info>
    <org_study_id>12/0533</org_study_id>
    <nct_id>NCT01882179</nct_id>
  </id_info>
  <brief_title>Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size</brief_title>
  <acronym>MINIMISE STEMI</acronym>
  <official_title>MINeralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (STEMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rosetrees Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart Hospital Charity Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hatter Cardiovascular Institute Trustees</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart attacks, or myocardial infarcts, are a major cause of death and disability in the UK.
      Immediate unblocking of the obstructed heart vessel with a balloon catheter and implantation
      of a mesh scaffold (stent) in heart centers is warranted in these patients. Morbidity and
      mortality in this patient group is related to the infarct size. Therefore, there is a need
      to discover novel therapeutic agents which reduce myocardial infarct size and preserve the
      contractile heart function.

      Large trials involving several thousand patients have demonstrated a survival benefit in
      patients with impaired heart function due to a heart attack, who received a
      mineralo-corticoid receptor antagonist (MRA, drug name: spironolactone). In these trials
      patients received the drug late, 3-14 days after the heart attack.

      Our proposal is to investigate whether MRA therapy administered intravenously  prior to
      unblocking an occluded heart vessel, can reduce infarct size and as such can prevent long
      term sequelae of heart attacks.

      150 patients admitted to 3 tertiary care hospitals (Heart Hospital London, London Chest,
      Essex Cardiothoracic Center Basildon) for heart attack will be randomly assigned to receive
      MRA treatment or placebo. The first dose of the MRA will be applied intravenously
      immediately in the catheter suite, even before re-opening of the occluded vessel. From the
      second day on, patients will be prescribed oral MRA treatment, as a pill, for a total of
      three months. Before hospital discharge and after three months, a magnetic resonance image
      (MRI) of the heart will accurately investigate the evolution of infarct (scar) size and the
      contractile heart function and compare the group of patients who received the MRA drug
      versus the placebo control group. Of note, patients with an ejection fraction &lt;40% AND signs
      of heart failure OR diabetes will go on open label eplerenone according to current
      guidelines, instead of the study drug.

      This study will give first evidence, if very early MRA treatment improves heart function and
      should be used as early as possible for treatment of patients after a heart attack.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Myocardial infarct (MI) size, as assessed by cardiac magnetic resonance imaging</measure>
    <time_frame>12 weeks after STEMI</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers of myocardial reperfusion injury</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>TIMI flow post-PPCI, ST-segment resolution post-PPCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular obstruction on cardiac MRI</measure>
    <time_frame>0-6 days after STEMI</time_frame>
    <safety_issue>No</safety_issue>
    <description>hypodense area of late gadolinium enhancement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial salvage</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area at risk assessed by T2 weighted imaging subtract final MI size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute myocardial infarct size</measure>
    <time_frame>2-6 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>serum biomarkers: hsTnT, CK-MB, CK and cardiac MRI: late gadolinium enhancement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV remodelling</measure>
    <time_frame>12 week cardiac MRI scan</time_frame>
    <safety_issue>No</safety_issue>
    <description>LV end-diastolic and end-systolic volumes, LV ejection fraction, LV mass and wall-thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome measures</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>cardiovascular death, non-fatal myocardial infarction, revascularisation, hospitalisation for heart failure, hyperkalemia, deterioration of kidney function, need for dialysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>ST-elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous saline bolus prior to PPCI followed by oral placebo for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mineralocorticoid receptor antagonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1st dose (day 0) given i.v. (potassium-canrenoate), before primary PCI day 1 - 12 weeks: spironolactone 25mg daily, which is uptitrated to 50mg daily after 2 weeks, if possible
In case the LVEF &lt;40% on baseline MRI and the patient shows signs of heart failure or is diabetic, the patient will receive open label eplerenone instead of the study drug, according to current guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mineralocorticoid receptor antagonist potassium-canrenoate</intervention_name>
    <arm_group_label>Mineralocorticoid receptor antagonist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria for entry into trial

          -  Patients &gt;18 years

          -  Patients presenting with acute STEMI (as assessed by 12 lead ECG; ST segment
             elevation ≥2 mm (0.2 mV) in 2 or more contiguous precordial leads or ≥1mm (0.1mm) in
             2 or more adjacent limb leads).

          -  Presentation within 12 hours after symptom onset

        Inclusion criteria for randomization (assessed in theatre)

          -  Angiographically proven proximal occlusion (TIMI 0) of a major coronary vessel (LAD,
             LCX, RCA).

          -  Normal potassium (&lt;5.0 mmol/l)

        Exclusion Criteria:

          -  Patients with known LVEF ≤40%

          -  Participation in another trial

          -  Cardiogenic shock (positive shock index OR need for catecholamine support OR systolic
             blood pressure &lt; 90 mmHg)

          -  Killip class &gt; 2

          -  Prior myocardial infarction

          -  Known compromised renal function (eGFR &lt; 30 ml/min/1.73 m2) or potassium &gt; 5.0 mmol/l

          -  Current treatment with mineralocorticoid receptor antagonists

          -  Pregnant or lactating females

          -  Allergies to IMP or its excipients

          -  Known contraindication to cardiac magnetic resonance imaging (MRI) such as
             significant claustrophobia, severe allergy to gadolinium chelate contrast, , presence
             of MRI contraindicated implanted devices (eg, pacemaker, implanted cardiac
             defibrillator, cardiac resynchronization therapy device, cochlear implant), imbedded
             metal objects (eg, shrapnel), or any other contraindication for cardiac MRI.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek J Hausenloy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University College London, Hatter Cardiovascular Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georg M Fröhlich, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University College London, The Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal Meier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London, The Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reto Gamma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Basildon and Thurrock University Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Mathur, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Derek J Hausenloy, PhD</last_name>
    <phone>+44 (0) 203 447 9894</phone>
    <email>d.hausenloy@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Georg M Fröhlich, MD</last_name>
    <phone>++44 79 640 958 38</phone>
    <email>georg.froehlich@gmx.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiothoracic Center - Basildon and Thurrock University Hospitals</name>
      <address>
        <city>Basildon</city>
        <state>Essex</state>
        <zip>SS16 5NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reto Gamma, MD</last_name>
      <email>retogamma@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Reto Gamma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Hospital London</name>
      <address>
        <city>London</city>
        <zip>W1G 8PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal Meier, MD</last_name>
      <email>pascalmeier74@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pascal Meier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Chest Hospital</name>
      <address>
        <city>London</city>
        <zip>E2 9JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony Mathur, PhD</last_name>
      <email>Emma.Bastian@bartshealth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anthony Mathur, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348(14):1309-21. Epub 2003 Mar 31. Erratum in: N Engl J Med. 2003 May 29;348(22):2271.</citation>
    <PMID>12668699</PMID>
  </reference>
  <reference>
    <citation>Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011 Jan 6;364(1):11-21. doi: 10.1056/NEJMoa1009492. Epub 2010 Nov 14.</citation>
    <PMID>21073363</PMID>
  </reference>
  <reference>
    <citation>Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17.</citation>
    <PMID>10471456</PMID>
  </reference>
  <reference>
    <citation>Schmidt K, Tissier R, Ghaleh B, Drogies T, Felix SB, Krieg T. Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion. Eur Heart J. 2010 Jul;31(13):1655-62. doi: 10.1093/eurheartj/ehp555. Epub 2009 Dec 21. PubMed PMID: 20028693; PubMed Central PMCID: PMC3063847.</citation>
    <PMID>20028693</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>June 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reperfusion injury</keyword>
  <keyword>myocardial infarct size</keyword>
  <keyword>MRI</keyword>
  <keyword>spironolactone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Canrenoate Potassium</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Aldosterone Antagonists</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
